Prognostic value of plasma sAXL in patients with heart failure: insights from the DRAGON-HF trial.

Yifan LiuXiaoyu WangXin PanTeng MaYawei XuQimao FenMuyesai NijiatiChen ChiYang SuXianling ZhangDachun Xu

Published in: ESC heart failure (2022)

Plasma sAXL concentrations are of great importance in predicting clinical outcomes in HF patients, independent of NT-proBNP, suggesting that sAXL is a promising prognostic marker for further study.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
clinical trial
peritoneal dialysis
study protocol
randomized controlled trial
heart failure
acute heart failure
phase iii
patient reported outcomes
atrial fibrillation